Low-intensity Focused Ultrasound and Autonomic Response

NCT ID: NCT05834829

Last Updated: 2025-06-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-02-22

Study Completion Date

2026-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Studying the effects of Low Intensity Focused Ultrasound (LIFU) to the dorsal posterior insula (dPI) and dorsal anterior cingulate cortex (dACC) on autonomic control using a test to probe the autonomic system. A cold pressor task will be performed pre and post LIFU application. Physiologic recordings will be recorded throughout.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Characterize the effect of LIFU to the bilateral dorsal posterior insula (dPI) and dorsal anterior cingulate cortex (dACC)) on autonomic control. The dPI is a critical brain area involved in autonomic function, being a core recipient of ascending pain and autonomic function. Similarly, the dACC has been strongly implicated in autonomic control and works with the insula for autonomic processing. Inconveniently, these brain regions lie deep to the cortex, prohibiting access using conventional noninvasive methods like transcranial magnetic stimulation (TMS). LIFU can be focused at depth to reach the insula and ACC with high spatial precision. However, the effect of LIFU to the human dPI and dACC on autonomic control is unknown. To address this, the investigators will target the right dPI and the dACC to assess how LIFU to each of these areas affects autonomic responses and subjective report to the cold pressor task, a safe, reproducible autonomic challenge.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Autonomic Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

three arm model, participants receive each intervention/sham (dPI, ACC, or Sham) one per study visit in a randomized order.
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors
Sham application during a single randomized session (1 of 3 sessions).

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

dPI

LIFU to the dPI

Group Type EXPERIMENTAL

Low-intensity focused ultrasound neuromodulation

Intervention Type DEVICE

ultrasound transducer applying low intensity waveforms to targeted brain regions for neuromodulation.

ACC

LIFU to the ACC

Group Type EXPERIMENTAL

Low-intensity focused ultrasound neuromodulation

Intervention Type DEVICE

ultrasound transducer applying low intensity waveforms to targeted brain regions for neuromodulation.

Sham

Sham LIFU application

Group Type SHAM_COMPARATOR

Sham Low-intensity focused ultrasound

Intervention Type DEVICE

sham application of ultrasound using blocking of the ultrasound waves of the transducer.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Low-intensity focused ultrasound neuromodulation

ultrasound transducer applying low intensity waveforms to targeted brain regions for neuromodulation.

Intervention Type DEVICE

Sham Low-intensity focused ultrasound

sham application of ultrasound using blocking of the ultrasound waves of the transducer.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

* Claustrophobia (scanning environment may be uncomfortable).
* Contraindications to MRI: including pacemaker, aneurysm clips, neurostimulators, cochlear implants, metal in eyes, steel worker, or other implants.
* Contraindications to CT: pregnancy
* Active medical disorder or treatment with potential central nervous system (CNS) effects (e.g. Alzheimer's) -
* History of neurologic disorder. (e.g. Parkinson's, Epilepsy, or Essential Tremor)
* History of head injury resulting in loss of consciousness for \>10 minutes.
* History of alcohol or drug dependence (through self-report).
* History of cardiac disease
* A current or prior use of any cardiac medication (e.g. beta blockers or other anti-arrhythmics)
* A history of diabetes mellitus or use of diabetic medications (e.g. metformin).
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Virginia Polytechnic Institute and State University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Wynn Legon

Assistant Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Fralin Biomedical Research Institute at VTC

Roanoke, Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

23-049

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Noninvasive Modulation of Chronic Neuropathic Pain
NCT06249724 WITHDRAWN PHASE1/PHASE2
Focused Ultrasound for the Treatment of Neuropathic Pain
NCT04485208 ENROLLING_BY_INVITATION NA